Biliary tract cancers (BTCs) are rare with poor prognosis. Due to the advent of genomic
sequencing, new data have emerged regarding the molecular makeup of this disease. To …

Growth factors and their corresponding receptors are commonly overexpressed and/or
dysregulated in many cancers including hepatocellular cancer (HCC). Clinical trials indicate …

Thrombocytopenia may be associated with increased bleeding risk impacting timing and
outcome of invasive procedures in patients with chronic liver disease (CLD) …

Background There is a high unmet clinical need for treatments of advanced/metastatic biliary
tract cancers after progression on first-line chemotherapy. Regorafenib has demonstrated …

Background: Advanced biliary tract carcinoma has a very poor prognosis, with
chemotherapy being the mainstay of treatment. Sorafenib, a multikinase inhibitor of VEGFR …

Background Advanced biliary tract carcinomas (BTCs) have poor prognosis and limited
therapeutic options. Therefore, it is crucial to combine standard therapies with molecular …

Reduced drug uptake is an important mechanism of chemoresistance. Down‐regulation of
SLC22A1 encoding the organic cation transporter‐1 (OCT1) may affect the response of …

Background Since sorafenib has shown activity in different tumour types and gemcitabine
regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated first-line …

Cholangiocarcinoma (CC) is an aggressive malignancy with an inferior prognosis due to
limited systemic treatment options. As preclinical models such as CC cell lines are extremely …

Vandetanib did not demonstrate any superiority alone or in combination with gemcitabine in
the progression-free survival of patients affected by advanced biliary tract cancer compared …